Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

54.14USD
3:05pm EDT
Change (% chg)

$0.59 (+1.10%)
Prev Close
$53.55
Open
$53.72
Day's High
$54.31
Day's Low
$53.72
Volume
884,474
Avg. Vol
2,956,439
52-wk High
$77.10
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Transgene and Bristol-Myers Squibb announce clinical research collaboration
1:33am EDT 

April 25 (Reuters) - Transgene Sa : :Co and Bristol-Myers Squibb announce clinical research collaboration to evaluate TG4010 with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer.Phase 2 clinical trial will explore potential of combining Transgene's TG4010, in conjunction with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo.Under terms of agreement, Transgene will be sponsor of trial. Bristol-Myers Squibb will provide Opdivo for use in study..  Full Article

Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer
Friday, 21 Apr 2017 02:06pm EDT 

April 21 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.CHMP opinion based on tumor response rate and duration of response demonstrated in phase 2 checkmate -275 trial.  Full Article

Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology
Monday, 17 Apr 2017 06:59am EDT 

April 17 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Nordic Bioscience announce collaboration for fibrosis biomarker technology.Collaboration to develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis.  Full Article

Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb
Thursday, 13 Apr 2017 07:00am EDT 

Biogen Inc : Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168 . Biogen Inc - Biogen will be responsible for full development and global commercialization of bms-986168 in ad and psp . Biogen Inc - to assume all remaining obligations to former stockholders of Ipierian, Inc related to Bristol-Myers Squibb's acquisition of company in 2014 . Biogen Inc - may pay up to $550 million in remaining milestones plus royalties including a near term $60 million milestone .Biogen Inc - announced an agreement to exclusively license BMS-986168 from Bristol-Myers Squibb.  Full Article

Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors
Tuesday, 11 Apr 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Apexigen, Inc. announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with APX005M in advanced solid tumors . Bristol-Myers - Study to evaluate potential of APX005M + Opdivo to activate antigen-presenting cells in tumor microenvironment to show anti-tumor activity . Bristol-Myers Squibb- Study to enroll second-line metastatic non-small cell lung cancer patients who have failed prior chemotherapy .Study to also enroll metastatic melanoma patients who have failed prior I-O therapy.  Full Article

FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer
Tuesday, 4 Apr 2017 04:15pm EDT 

Bristol-myers Squibb Co : U.S. Food and Drug Administration accepts for priority review Bristol-Myers Squibb's application for Opdivo (nivolumab) in previously treated DMMR or MSI-H metastatic colorectal cancer .Bristol-Myers Squibb Co - FDA granted application priority review, and FDA action date is August 2, 2017.  Full Article

Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo
Friday, 24 Mar 2017 08:31am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy . Bristol-Myers Squibb Co - positive opinion based on overall survival benefit demonstrated in phase 3 checkmate -141 trial . Bristol-Myers Squibb Co- safety profile of opdivo in checkmate -141 was consistent with prior studies in other tumors .Bristol-Myers Squibb - CHMP recommendation will now be reviewed by European Commission.  Full Article

Heat Biologics reports positive results from mid-stage lung cancer trial
Tuesday, 21 Mar 2017 07:00am EDT 

Heat Biologics Inc : Heat Biologics reports positive interim phase 2 lung cancer results in patients treated with hs-110 in combination with a checkpoint inhibitor . Immune responses to hs-110 were observed in all 5 patients that exhibited tumor reductions .No tumor reductions were observed in patients that did not mount an immune response to hs-110.  Full Article

Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration
Monday, 20 Mar 2017 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers Squibb and Cytomx Therapeutics extend worldwide collaboration to discover Probody Therapeutics for the treatment of cancer and other diseases . Bristol-Myers Squibb Co - Cytomx to receive $200 million upfront payment . Bristol-Myers Squibb - Cytomx will also be eligible to receive up to $448 million in future development, regulatory,sales milestone payments for each collaboration target . Bristol-Myers Squibb Co - collaboration includes up to eight additional targets in oncology and other therapeutic areas .Bristol-Myers Squibb Co - Cytomx will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probody Therapeutics.  Full Article

Transgene SA says first results from Phase 2 trial could be expected from end of 2017
Monday, 13 Mar 2017 01:00pm EDT 

Transgene SA : First patient dosed in Phase 2 trial evaluating Transgene's TG4010 in combination with Opdivo(nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (NSCLC) .First results from Phase 2 trial could be expected from end of 2017.  Full Article

More From Around the Web

U.S. Supreme Court may limit where companies can be sued

WASHINGTON U.S. Supreme Court justices on Tuesday signaled a willingness to place limits on where corporations can be sued in a dispute involving drug maker Bristol-Myers Squibb Co, a potential setback to plaintiffs' lawyers who try to bring suits in friendly courts.